CD38 and Miyoshi myopathy: The wide expression of CD38 in hematological malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia (CLL), ALL, AML, and NK-cell leukemias (reviewed in [77]), has made this antigen an attractive molecule for immunotherapeutic strategies.